Measles spikes across Canada due to anti-vax ‘recklessness,' B.C. premier says
VANCOUVER — British Columbia Premier David Eby says the growing spread of measles across Canada is 'the sadly predictable outcome' of the 'recklessness' of anti-vaccination politicians.
Eby says the disease is 'no joke,' given the potentially serious impact on those infected, and it's preventable with two vaccine shots.
He told a Vancouver news conference that the focus for provincial public health authorities now is to make sure that people who are not protected receive full vaccination.
The premier's response comes after Fraser Health said this week that three residents in Chilliwack have been confirmed as being infected and all appear to have contracted the disease locally since they have not recently travelled.
Health authorities elsewhere in the province have also reported cases in Kamloops and the community of Wonowon in northeastern B.C., northwest of Fort St. John.
Ontario reported its first death in the measles outbreak on June 5 when a premature baby died after being infected in the womb of its unvaccinated mother.
Thousands in Ontario have been infected since October, while Alberta's government said last week that it has also surpassed a thousand confirmed measles cases, most of them in children age five to 17.
Health Canada says measles was eliminated in the country in 1998, and the spike in Alberta has been the most severe in almost 40 years.
'This is the sadly predictable outcome of some recklessness, frankly, on the parts of some politicians in terms of questioning vaccine safety and ensuring that people are supported in accessing vaccines,' Eby said without naming people or provinces.
'I will encourage all British Columbians to ensure that they are vaccinated. Measles is no joke. It kills kids. It's a preventable disease, and we don't want that to be the story of the summer for our province.'
This report by Chuck Chiang, The Canadian Press, was first published June 25, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
41 minutes ago
- Cision Canada
XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications Français
XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis MARKHAM, ON, June 26, 2025 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that XTANDI ® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis (high-risk BCR). i This decision means XTANDI is now publicly reimbursed in Ontario for all of its approved prostate cancer indications. Health Canada granted Astellas market authorization for XTANDI in nmCSPC in January 2024. This approval was expedited as a result of XTANDI's inclusion in Project Orbis, an initiative of regulatory bodies, including Health Canada, with an aim to give patients faster access to promising cancer treatments in some countries around the world. The swift decision to reimburse XTANDI in Ontario is an important milestone towards making this important therapy available to Ontarians. "The public reimbursement of XTANDI in Ontario is important because it expands access to a vital treatment for prostate cancer patients who are at high risk of metastasis," said Tony Finelli, MD, FRCSC, Professor of Surgery and Chair of Urology, University of Toronto, Urologic Oncologist, University Health Network (UHN). "Reducing the barriers to accessing XTANDI allows us as physicians to offer even more comprehensive care to those navigating the challenges of living with prostate cancer." "We applaud Ontario's decision to publicly reimburse XTANDI for the treatment of nmCSPC patients with high-risk BCR," said Sandra Heller, General Manager, Astellas Pharma Canada. "At Astellas, we remain dedicated to ensuring that patients have access to the therapies they require for better health outcomes, and we are honoured to support men facing this difficult journey." Reimbursement Criteria Specific reimbursement criteria must be met for public coverage of XTANDI. Complete information can be found by consulting the Ontario Drug Benefit Program under the Exceptional Access Program for details. About nmCSPC Prostate cancer develops when abnormal cells form and grow in the prostate gland. ii nmCSPC describes the early stage of prostate cancer wherein the disease remains localized and still responds to medical or surgical treatment to lower testosterone levels. iii Of men who have undergone definitive prostate cancer treatment, including radical prostatectomy, radiotherapy, or both, an estimated 20-40 per cent will experience a biochemical recurrence (BCR) within 10 years. iv About 9 out of 10 men with high-risk BCR will develop metastatic disease, and 1 in 3 will die as a result of their metastatic prostate cancer. v As the most common cancer among Canadian men, prostate cancer accounts for an average of 76 new diagnosis every day. vi It is estimated that about 1 in 8 Canadian men will develop prostate cancer during their lifetime and 1 in 30 will die from it. vii Approximately 98 per cent of cases occur in men above the age of 50. viii About XTANDI (enzalutamide) XTANDI is an androgen receptor (AR) inhibitor that overcomes resistance to conventional antiandrogens by inhibiting AR signaling at multiple steps in the pathway. ix XTANDI is approved for use in men in four prostate cancer disease states across five indications: The treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR). The treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). The treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients: chemotherapy-naïve and post-docetaxel Please consult the Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available by calling Astellas Medical Information at 1-888-338-1824. XTANDI is a standard of care that has received regulatory approvals in more than 90 countries, including the United States, the European Union and Japan. About XTANDI Patient Assistance Program Astellas is committed to supporting patients prescribed XTANDI through the XTANDI Patient Assistance Program by offering coverage navigation, financial assistance, patient and caregiver education as well as specialty pharmacy dispensing. Patients with a valid prescription can be enrolled by calling 1-855-982-6348. About Astellas Pharma Canada Astellas Pharma Canada, Inc. is a Canadian affiliate of Tokyo-based Astellas Pharma Inc., a global life sciences company conducting business in more than 70 countries around the world. Astellas is committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at SOURCE Astellas Pharma Canada, Inc.
Globe and Mail
44 minutes ago
- Globe and Mail
Does your kid use headphones or earbuds? These four tips can help keep young ears safe
No matter where you look these days, people are using headphones or earbuds. Whether for school, work or leisure, they seem to have become a necessary accessory for adults and children alike. However, experts say using headphones or earbuds at high volumes for too long can lead to noise-induced hearing loss. And while this can happen at any age, there's growing concern about the impact on young ears. A 2022 study published in the journal BMJ Global Health found that unsafe listening practices – from both personal listening devices and loud entertainment venues – could place more than 1 billion people aged 12-34 at risk of hearing loss. No, your teen shouldn't rot in front of a screen all summer Valerie Simard, an audiologist and clinical manager of communication disorders and otolaryngology at SickKids in Toronto, said she has seen more children come to SickKids with hearing problems in recent years than in the past. Prolonged exposure to loud noise can permanently damage the hair cells in the cochlea – the inner part of the ear – which are essential for hearing, explained Simard. Tweens and teens are at high risk because they spend so much time using headphones or earbuds for gaming, listening to music or social media. But younger children can also be vulnerable since their auditory systems are still developing and their ear canals are smaller, meaning it takes less noise to cause damage. Some people may also develop hypersensitivity to sound, said Dr. Anne Woolliams, a registered audiologist and owner of Soundwave Hearing Care, a hearing loss clinic with several sites in Alberta. She said her clinics are seeing more kids with this issue, especially those who spend a lot of time gaming. 'They game eight, 10 hours a day where they're wearing noise-cancelling headphones,' Dr. Woolliams said. This means when they take their headphones off, it can be harder to process typical sounds in the world around them. Is your kid 18? Here are 11 life skills they should have mastered by now Fortunately, experts say using headphones or earbuds is not all bad. In fact, early exposure to literacy resources and music with headphones can be a good auditory training tool for the brain if used in moderation, explained Dr. Woolliams. However, following practices that can help minimize the risks and protect hearing is crucial. Limit the volume and take breaks Both Simard and Dr. Woolliams suggest following the 60-60 rule: listening at 60 percent of the device's maximum volume for 60 minutes, followed by a break. For younger kids, Simard advises parents to activate the volume control on devices. 'Teenagers can easily override these, but for the younger kids, it's a good option,' she said. Another strategy Simard advocates is the arms-length test: 'Someone listening under headphones or using earbuds should still be able to hear a speaker at arm's length speaking at a normal conversational level.' Don't use them to drown out background noise Dr. Susan Scollie, a professor in the faculty of health sciences and director of the National Centre for Audiology at the University of Western Ontario, says cranking the volume to cover up background noise – such as on a noisy subway or plane – increases the risk of damage. 'What's a better idea is headphones that actually physically block the sound or that have the noise reduction built into the headphones, rather than making the music louder,' she said. Three money topics to tackle with your teenager as university acceptance letters arrive However, Dr. Scollie said, people should consider what type of device is best suited to the environment they're in. For example, if you are walking down the street and need to be able to hear the sound of traffic, then regular earbuds – which still allow some background noise to be heard – are preferable to noise-reducing headphones. Be intentional about when to use them Dr. Woolliams, who is also a clinical assistant professor at the University of British Columbia's school of audiology and speech sciences, encourages people to be intentional about how and when they use personal listening devices. 'Use the headphones when you want to study and focus, but if you're having a conversation with someone, take it off, take breaks,' she said. 'Especially with earbuds, don't just have them lingering in your ear. Use them actively and then when you don't need them, take them out, because even just having a dead earbud in your ear, you're blocking the normal signal of the world coming in.' For the youth and adolescent brain, she said, this can lead to hypersensitivity to sound, delays or atypical auditory processing skills and hearing loss in one ear. Recognize the signs of hearing loss While prevention is the best medicine, it's also important to recognize the early signs of noise-induced hearing loss or hypersensitivity, so you know when to seek help. According to Dr. Woolliams, the signs can be subtle but if a kid is complaining that things are too loud, struggling to hear or taking longer to process information – it may be time to go see an audiologist. Other signs include asking for frequent repetitions, complaining that the sound is muffled or experiencing a ringing in the ears, called tinnitus. But Simard cautions that it can take a long time for the impact of hearing loss to become noticeable, which is why safe listening education for youth is key. Dr. Scollie agrees it's important to talk to kids about how to prevent noise-induced hearing loss. 'My kids both wear earbuds all the time. I can't make them not, they're teenagers. I've talked with them about safety from two points of view, one is not getting hit by a car and two is not damaging your hearing.' She puts her advice simply: 'Don't crank it up too loud, don't listen to it for too long, but enjoy it when you are.'
Globe and Mail
an hour ago
- Globe and Mail
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program
Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program NASDAQ| TSX: ACB EDMONTON, AB, June 26, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through
